<DOC>
	<DOCNO>NCT00025389</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill deliver cancer-killing substance . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy surgery may may shrink tumor remove . PURPOSE : This phase II trial see bevacizumab , paclitaxel , carboplatin give surgery work treat patient stage IB , stage II , stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Bevacizumab , Paclitaxel , Carboplatin Before Surgery Treating Patients With Stage IB , Stage II , Stage IIIA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical complete partial response rate patient stage IB , II , IIIA resectable non-small cell lung cancer treat neoadjuvant bevacizumab , paclitaxel , carboplatin . - Determine pathologic complete response rate patient treat regimen . - Determine ability proceed complete potentially curative resection patient treat regimen . - Determine safety toxicity regimen patient . OUTLINE : Patients receive neoadjuvant bevacizumab IV 60-90 minute , paclitaxel IV 3 hour , carboplatin IV 1 hour day 1 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Patients undergo surgical resection within 4-6 week completion chemotherapy . Patients follow within 3 month . PROJECTED ACCRUAL : A total 23-39 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IB ( T2 , N0 ) , II ( T1 T2 , N1 T3 , N0 ) , IIIA ( T3 , N1 ) Potentially resectable disease No large central primary tumor proximity significant blood vessel No bronchoscopically evident endobronchial tumor At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 OR Karnofsky 70100 % Life expectancy : More 12 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No history inherit bleed disorder No inherited predisposition hypercoagulable state No clinically evident hypercoagulable state bleeding diathesis Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN INR le 1.5 PTT less 36 second Renal : Creatinine le 1.5 time ULN OR Creatinine clearance least 60 mL/min No nephrotic syndrome Urine protein great 0.5 g/24 hour Cardiovascular : No poorly control hypertension ( great 150 mm Hg systolic and/or great 100 mm Hg diastolic ) despite treatment No uncompensated coronary artery disease No myocardial infarction within past 6 month No clinically significant severe peripheral vascular disease No inherited predisposition thrombosis No deep venous arterial thrombosis No symptomatic congestive heart failure No unstable angina pectoris within past 6 month No cardiac arrhythmia No transient ischemic attack within past 6 month No cerebrovascular accident within past 6 month No arterial thromboembolic event within past 6 month Pulmonary : No hemoptysis No pulmonary embolism Other : No history allergic reaction compound similar chemical biologic composition study drug No know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric illness social situation would preclude study compliance No significant traumatic injury within past 28 day No uncontrolled concurrent illness No ongoing active infection No serious , nonhealing wound , ulcer , bone fracture No active malignancy No requirement fulldose anticoagulation thrombolytic therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy cancer No concurrent prophylactic growth factor ( e.g. , epoetin alfa , filgrastim [ GCSF ] , sargramostim [ GMCSF ] ) Chemotherapy : No prior chemotherapy cancer Prior chemotherapy another malignancy allow provide prior malignancy curatively treat currently control Endocrine therapy : No prior endocrine therapy cancer Radiotherapy : No prior radiotherapy cancer Prior radiotherapy another malignancy allow provide prior malignancy curatively treat currently control No concurrent radiotherapy Surgery : Prior diagnostic bronchoscopy , mediastinoscopy , CTguided biopsy allow At least 28 day since prior major surgical procedure open biopsy Other : No concurrent investigational agent No concurrent anticancer investigational commercial agent therapies No concurrent combination antiretroviral therapy HIVpositive patient Concurrent lowdose warfarin maintenence preexisting , permanent , indwell IV catheter allow provide INR less 1.5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>